Skip to main content
Journal cover image

The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.

Publication ,  Journal Article
Havrilesky, LJ; Scott, AL; Davidson, BA; Secord, AA; Yang, J-C; Johnson, FR; Gonzalez, JM; Reed, SD
Published in: Gynecol Oncol
August 2021

OBJECTIVE: To assess preferences of women with ovarian cancer regarding features of available anti-cancer regimens for platinum-resistant, biomarker-positive disease, with an emphasis on oral PARP inhibitor and standard intravenous (IV) chemotherapy regimens. METHODS: A discrete-choice-experiment preferences survey was designed, tested, and administered to women with ovarian cancer, with 11 pairs of treatment profiles defined using seven attributes (levels/ranges): regimen (oral daily, IV weekly, IV monthly); probability of progression-free (PFS) at 6 months (40%-60%); probability of PFS at 2 years (10%-20%); nausea (none, moderate); peripheral neuropathy (none, mild, moderate); memory problems (none, mild); and total out-of-pocket cost ($0 to $10,000). RESULTS: Of 123 participants, 38% had experienced recurrence, 25% were currently receiving chemotherapy, and 18% were currently taking a PARP inhibitor. Given attributes and levels, the relative importance weights (sum 100) were: 2-year PFS, 28; cost, 27; 6-month PFS, 19; neuropathy,14; memory problems, nausea, and regimen, all ≤5. To accept moderate neuropathy, participants required a 49% (versus 40%) chance of PFS at 6 months or 14% (versus 10%) chance at 2 years. Given a 3-way choice where PFS and cost were equal, 49% preferred a monthly IV regimen causing mild memory problems, 47% preferred an oral regimen causing moderate nausea, and 4% preferred a weekly IV regimen causing mild memory and mild neuropathy. CONCLUSIONS: These findings challenge the assumption that oral anti-cancer therapies are universally preferred by patients and demonstrate that there is no "one size fits all" regimen that is preferable to women with ovarian cancer when considering recurrence treatment regimens.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 2021

Volume

162

Issue

2

Start / End Page

440 / 446

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Severity of Illness Index
  • Progression-Free Survival
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Patient Preference
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neurotoxicity Syndromes
  • Neoplasm Recurrence, Local
  • Nausea
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Havrilesky, L. J., Scott, A. L., Davidson, B. A., Secord, A. A., Yang, J.-C., Johnson, F. R., … Reed, S. D. (2021). The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecol Oncol, 162(2), 440–446. https://doi.org/10.1016/j.ygyno.2021.05.022
Havrilesky, Laura J., Amelia L. Scott, Brittany A. Davidson, Angeles Alvarez Secord, Jui-Chen Yang, F Reed Johnson, Juan Marcos Gonzalez, and Shelby D. Reed. “The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.Gynecol Oncol 162, no. 2 (August 2021): 440–46. https://doi.org/10.1016/j.ygyno.2021.05.022.
Havrilesky LJ, Scott AL, Davidson BA, Secord AA, Yang J-C, Johnson FR, et al. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecol Oncol. 2021 Aug;162(2):440–6.
Havrilesky, Laura J., et al. “The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.Gynecol Oncol, vol. 162, no. 2, Aug. 2021, pp. 440–46. Pubmed, doi:10.1016/j.ygyno.2021.05.022.
Havrilesky LJ, Scott AL, Davidson BA, Secord AA, Yang J-C, Johnson FR, Gonzalez JM, Reed SD. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecol Oncol. 2021 Aug;162(2):440–446.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 2021

Volume

162

Issue

2

Start / End Page

440 / 446

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Severity of Illness Index
  • Progression-Free Survival
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Patient Preference
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neurotoxicity Syndromes
  • Neoplasm Recurrence, Local
  • Nausea